PDSS2

Across TCGA pan-cancer cohorts, PDSS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDSS2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDSS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDSS2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where PDSS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.886	.002	27	view →
PDAC	OS	Tertile	II,III,IV	0.682	0.356	.015	7	view →
LSCC	OS	Median	All	0.929	0.845	.021	6	view →
GBM	OS	Median	All	0.890	0.743	.006	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDSS2–CCRCC (OS)

Open the CCRCC breakdown →